LEGN Stock Down -15% after 10-Day Loss Streak
Legend Biotech (LEGN) stock hit day 10 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -15% return. The company has lost about $1.1 Bil in value over the last 10 days, with its current market capitalization at about $7.1 Bil. The stock remains 15.7% above its value at the end of 2024. This compares with year-to-date returns of 7.9% for the S&P 500.
LEGN develops novel cell therapies for oncology, including a lead CAR therapy for multiple myeloma and early-stage autologous candidates in clinical trials for gastric cancer and T cell lymphoma. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell LEGN.
Comparing LEGN Stock Returns With The S&P 500
The following table summarizes the return for LEGN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | LEGN | S&P 500 |
|---|---|---|
| 1D | -2.0% | 0.7% |
| 10D (Current Streak) | -15.0% | -0.2% |
| 1M (21D) | 0.5% | 1.9% |
| 3M (63D) | 20.1% | 13.2% |
| YTD 2025 | 15.7% | 7.9% |
| 2024 | -45.9% | 23.3% |
| 2023 | 20.5% | 24.2% |
| 2022 | 7.1% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: LEGN Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 86 S&P constituents with 3 days or more of consecutive gains and 15 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 65 | 7 |
| 4D | 17 | 2 |
| 5D | 4 | 1 |
| 6D | 0 | 4 |
| 7D or more | 0 | 1 |
| Total >=3 D | 86 | 15 |
Key Financials for Legend Biotech (LEGN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $285.1 Mil | $627.2 Mil |
| Operating Income | $-439.5 Mil | $-303.2 Mil |
| Net Income | $-518.3 Mil | $-177.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $186.5 Mil | $195.1 Mil |
| Operating Income | $-74.4 Mil | $-50.6 Mil |
| Net Income | $26.3 Mil | $-100.9 Mil |
The losing streak LEGN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.